Multidrug resistance associated with altered topoisomerase II activity--topoisomerases II as targets for rational drug design.
Morrow
C S
CS
Medicine Branch, National Cancer Institute, Bethesda, MD 20892.
Cowan
K H
KH
D000970:Antineoplastic Agents / Q000494:pharmacology*; D015195:Drug Design; D004351:Drug Resistance; D006801:Humans; D059005:Topoisomerase II Inhibitors
D000970:Antineoplastic Agents; D059005:Topoisomerase II Inhibitors